SELLAS Life Sciences Group, Inc.
Conduct interim safety and futility analysis for the Phase 3 REGAL study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Nov 2021
- Due
- 31 Dec 2022
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company now anticipates that the interim analysis will take place in the second half of 2022”
What we found
Evidence strength A What the grades mean
The company did not conduct the interim analysis by the end of 2022; filings from 2024 indicate that the required number of events for the analysis was only reached later.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2024-03-28
“In the fourth quarter of 2023, we announced that we had exceeded our target enrollment of 105 patients... and exceeded the number of patients needed for the pre-specified interim and final analyses (60/80).” ✓ confirmed on the page
Market reaction: the shares moved +15.4% against the S&P 500 over the three sessions around the disclosure (27 Mar 2024 to 2 Apr 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +731 days
- Scope drift 0.0%
- 5 versions
-
Version 1 · original · stated 12 Nov 2021
Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected
-
Version 2 · stated 6 Apr 2022
Deadline 30 Jun 2023 (“by the end of the first half of 2023”) · wording expected
“with a planned interim analysis by the end of the first half of 2023”
-
Version 3 · stated 15 Nov 2022
Deadline 31 Mar 2024 (“late '23 or early '24”) · target 60 events · wording expected
“the targeted number of events or deaths for the interim analysis will be reduced to 60 from 80, and is expected to occur sometime in late '23 or early '24.”
-
Version 4 · stated 13 Aug 2024
Deadline 31 Dec 2024 (“by Q4 2024”) · wording expected
“Interim Analysis Anticipated by Q4 2024”
-
Version 5 · stated 13 Nov 2024
Deadline 31 Dec 2024 (“fourth quarter of 2024”) · target 60 events · wording firm
“the interim analysis (60 events) will occur in the fourth quarter of 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Conduct
- Deliverable
- interim safety and futility analysis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: provided that the ongoing COVID-19 pandemic does not continue to adversely impact the projected timeline for enrollment
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-SLS-001986 · Corrections policy